AMAnn Dorothy Morgan

Ann Dorothy Morgan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ann Dorothy Morgan has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    End of rarity: the evolving burden of interstitial lung diseases in England – trends from a national population-based cohort study

    by Georgie May Massen, Ann Dorothy Morgan, Peter M George, Jennifer K Quint, Vidya Navaratnam

    Background: The disease burden from interstitial lung diseases (ILDs) is thought to be increasing globally, but there is a paucity of data on epidemiological trends in non-idiopathic pulmonary fibrosis (IPF) ILD. We calculated incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD in England from 2005 to 2022 and investigated trends over time. Methods: Using linked primary and secondary electronic healthcare records, we used three code-based algorithms to estimate incidence, prevalence and mortality rates of all ILD, IPF and non-IPF ILD subtypes. We additionally stratified our results by sex, age-group and region. Poisson regression was used to investigate changes to trends over time. We used Kaplan-Meier methods to calculate median survival. Results: There were 153 975 incident cases of ILD in either primary or secondary care records. Incidence rates of all ILD, IPF and non-IPF ILD were 30% higher in 2022 compared with 2005, with rates plateauing from 2018 onwards. The prevalence of IPF and non-IPF ILD increased by 6% and 7%, respectively, over the study period. Mortality rates adjusted for age and sex in people with all ILD and non-IPF ILD were similar in 2022 compared with 2005 but in people with IPF it was 15% lower. Median survival of our overall ILD cohort was 5.4 years (IQR 1.88–13.03). Conclusions: Our population-based study highlights that ILD are no longer rare. Currently, there are 200 000 people living with ILD and 60 000 new cases are diagnosed each year. Healthcare and research funding needs to reflect this growing burden.

  • Open Access

    Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study

    by Ann D. Morgan, Georgie M. Massen, Hannah R. Whittaker, Iain Stewart, Gisli Jenkins, Peter M. George, Jennifer K. Quint

    Background: A growing body of evidence suggests that prolonged use of inhaled corticosteroids (ICS) and proton pump inhibitors (PPIs) is associated with increased risks of pneumonia. A substantial proportion of people with idiopathic pulmonary fibrosis (IPF) are prescribed PPIs or ICS to treat common comorbidities, giving rise to concerns that use of these medications may be associated with potential harms in this patient population. Methods: We used UK Clinical Practice Research Datalink (CPRD) Aurum primary care data linked to national mortality and hospital admissions data to create a cohort of people diagnosed with IPF on or after 1 January 2010. Patients were assigned to one of three exposure categories according to their prescribing history in the 12 months prior to IPF diagnosis as follows: “regular” users (≥ 4 prescriptions), “irregular” users (1–3 prescriptions) and “non-users” (no prescriptions). We explored the association between PPI/ICS prescription and pneumonia hospitalisation and all-cause mortality using multinomial Cox regression models. Results: A total of 17,105 people met our study inclusion criteria; 62.6% were male and 15.9% were current smokers. Median age at IPF diagnosis was 76.7 years (IQR: 69.6–82.7). 19.9% were regularly prescribed PPIs, and 16.0% ICS, prior to IPF diagnosis. Regular prescribing of PPIs and ICS was positively associated with hospitalisation for pneumonia; the adjusted HR for pneumonia hospitalisation comparing regular PPI users with non-users was 1.14 (95%CI: 1.04–1.24); for regular ICS users the corresponding HR was 1.40 (95%CI: 1.25–1.55). We also observed a small increased risk for all-cause mortality in the “regular ICS user” group compared with the “non-user” control group (HRadj = 1.19, 1.06–1.33). We found no evidence of an association between PPI prescribing and all-cause mortality. Conclusion: Prolonged prescription of medications used to treat common comorbidities in IPF may be associated with increased risks for severe respiratory infections. These findings point to a need to adopt an adequate risk–benefit balance approach to the prescribing of ICS-containing inhalers and PPIs in people with IPF without evidence of comorbidities, especially older patients and/or those with more advanced disease in whom respiratory infections are more likely to result in poorer outcomes.


  • Open Access

    Referral to pulmonary rehabilitation and palliative care services in people with idiopathic pulmonary fibrosis in England, 2010–2019

    by Ann D. Morgan, Hakeem Khan, Peter M. George, Jennifer K. Quint

    The benefits of pulmonary rehabilitation (PR) and palliative care (PC) as non-pharmacological therapies for people with idiopathic pulmonary fibrosis (IPF) are increasingly being recognised but in the UK the proportion of people with this life-limiting condition who are referred to such services is thought to be low. This retrospective cohort study aimed to describe trends in referrals to PR and PC services among people with IPF over a 10-year period and to identify factors associated with non-referral. Our study cohort was drawn from the UK’s pseudonymised Clinical Practice Research Datalink (CPRD) Aurum primary care database and comprised 17,071 individuals diagnosed with IPF between 2010 and 2019. While 12.0% of IPF patients were offered a referral to PR, less than 2% completed a PR programme. Around a fifth (19.4%) received a referral to generic PC support services; however, this is well below reported PC referral rates for lung cancer patients. Moreover, the majority of PC referrals occurred late; among those who died, 31% were referred within a month and 70% within 6 months of death. Referrals to PR and PC had however increased (by around 2–fold and 4-fold, respectively) over the course of the study period. Factors associated with non-referral to PR included female sex, older age and co-diagnosis of dementia; barriers to PC referral included being female or of Asian or Black ethnicity. We also found evidence of regional differences in referrals. These findings confirm that PR and PC service provision for people with IPF across England is suboptimal.


  • Changes in survival in people with IPF in England 2010–2020

    by Ann Morgan, Rikisha Shah Gupta, Peter George, Jennifer Quint

    Background: Despite trial evidence of benefit, it is unknown whether survival has improved in the UK IPF population since the introduction of antifibrotics in the mid-2010s. Methods: Using linked Clinical Practice Research Datalink Aurum & Hospital Episode Statistics data, we calculated median survival times for patients diagnosed with IPF in 2010 and each year thereafter until 2018. For 2010–2020, we estimated age-and sex-adjusted hazard ratios for death (relative to 2010) and age-and sex-standardized all-cause mortality rates. We repeated our analyses using four differently-defined cohorts to explore whether survival and mortality trends were sensitive to coding choices for IPF case finding.1 Results: In our study population (n=46,527) there was no significant difference in median survival (years) between those newly-diagnosed in 2010 and 2018 [Aurum narrow cohort=4.6 (95%CI,3.7–5.4) vs 3.7(3.4–4.3); Aurum broad cohort=3.7(3.4–4.0) vs 4.2(3.8–4.4)]. Age-and sex-adjusted Cox models with all-cause mortality as the outcome also provided no evidence of improved survival but age-and sex-standardized mortality rates increased over the study period (Fig.) These trends were independent of IPF case definitions. Conclusion: Between 2010 and 2020, survival time among IPF patients remained unchanged while the mortality rate increased. Longer follow-up time is needed to fully assess the impact of antifibrotics in this population. 1 Morgan et al. BMC Pulm Med. 2023;23:256. erj;64/suppl_68/PA5146/F1 F1 F1

  • Open Access

    Patient pathways for four major chronic respiratory diseases in England between 2008 and 2021

    by Anne E Ioannides, Ann D Morgan, Jennifer K Quint

    Background Not all chronic diseases have clear pathways and time targets for diagnosis. We explored pathways and timings for four major chronic respiratory diseases in England. Methods Using deidentified electronic healthcare records from Clinical Practice Research Datalink Aurum linked to Hospital Episode Statistics, we derived cohorts of patients diagnosed with asthma, chronic obstructive pulmonary disease (COPD), ILD or bronchiectasis at three time periods (2008/2009, 2018/2019 and 2020/2021). We followed people 2 years before and 2 years after diagnosis, calculating the proportion of people who presented with symptoms, underwent diagnostic tests, were treated and consulted healthcare (primary or secondary) and calculated time intervals between events. We repeated analyses by socioeconomic status and geographical region. Results We descriptively studied patient pathways for 429 619 individuals across all time frames and diseases. Most people (>87%) had first evidence of diagnosis in primary care. The proportion of people reporting symptoms prior to diagnosis was similar for asthma, COPD and ILD (41.0%–57.9%) and higher in bronchiectasis (67.9%–71.8%). The proportion undergoing diagnostic tests was high for COPD and bronchiectasis (77.6%–89.2%) and lower for asthma (14%–32.7%) and ILD (2.6%–3.3%). The proportion of people undergoing diagnostic tests decreased in 2020/2021 for all diseases, mostly COPD. Time (months) (median (IQR)) between symptoms and diagnosis, averaged over three time periods, was lowest in asthma (~7.5 (1.3–16.0)), followed by COPD (~8.6 (1.8–17.2)), ILD (~10.1 (3.6–18.0)) and bronchiectasis (~13.5 (5.9–19.8)). Time from symptoms to diagnosis increased by ~2 months in asthma and COPD over the three time periods. Although most patients were symptomatically treated prior to diagnosis, time between diagnosis and postdiagnostic treatment was around 4 months for ILD, 3 months for bronchiectasis and instantaneous for asthma and COPD. Socioeconomic status and regional trends showed little disparity. Conclusion Current pathways demonstrate missed opportunities to diagnose and manage disease and to improve disease coding.


  • Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in England from 2008 to 2018: a cohort study

    by Rikisha Gupta, Ann Dorothy Morgan, Peter M George, Jennifer K Quint

    Background Owing to discrepancies in methodologies and how idiopathic pulmonary fibrosis (IPF) is diagnosed it is challenging to establish a consistent understanding of the disease burden In the UK, over 10 years ago, the incidence and prevalence of IPF were reported as 2.8–8.7 per 100 000 person-years (from 2000 to 2012) and 39 per 100 000 persons (in 2012), respectively. Here, we estimated the incidence and prevalence of IPF in England from 2008 to 2018 and investigated IPF mortality. Methods Using Clinical Practice Research Datalink Aurum and Hospital Episode Statistics (HES) linked datasets, we estimated incidence and prevalence using four validated diagnostic-code-based algorithms. Using the registered number of deaths (from Office of National Statistics) with the underlying cause being recorded as IPF, we estimated IPF mortality for the same period. Results Using Aurum-based definitions, incidence increased over time by 100% for Aurum narrow (3–6.1 per 100 000 person-years) and by 25% for Aurum broad (22.4–28.6 per 100 000 person-years). However, using HES-based definitions showed a decrease in incidence over the same period and lay between the two extremes derived for Aurum-based definition. IPF mortality in 2018 was 7.9 per 100 000 person-years and increased by 53% between 2008 and 2018. Interpretation When using best-case definitions, incidence rose throughout the study period. Scaling this to England’s population (2018), our best estimate would be in the range of 8000–9000 new cases per year which is higher than previously reported estimates (5000–6000). This increased burden in the new cases of IPF each year impacts future health service planning and resource allocation.


  • Open Access

    Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study

    by Ann D Morgan, Georgie M Massen, Hannah R Whittaker, Iain Stewart, Gisli Jenkins, Peter M George, Jennifer K Quint

    BackgroundA growing body of evidence suggests that prolonged use of inhaled corticosteroids (ICS) and proton pump inhibitors (PPIs) is associated with increased risks of pneumonia. A substantial proportion of people with idiopathic pulmonary fibrosis (IPF) are prescribed PPIs or ICS to treat common comorbidities, giving rise to concerns that use of these medications may be associated with potential harms in this patient population.MethodsWe used UK Clinical Practice Research Datalink (CPRD) Aurum primary care data linked to national mortality and hospital admissions data to create a cohort of people diagnosed with IPF on or after 1 January 2010. Patients were assigned to one of three exposure categories according to their prescribing history in the 12 months prior to IPF diagnosis as follows: “regular” users (≥4 prescriptions), “irregular” users (1–3 prescriptions) and “non-users” (no prescriptions). We explored the association between PPI/ICS prescription and pneumonia hospitalisation and all-cause mortality using multinomial Cox regression models.ResultsA total of 17,105 people met our study inclusion criteria; 62.6% were male and 15.9% were current smokers. Median age at IPF diagnosis was 76.7 years (IQR: 69.6–82.7). 19.9% were regularly prescribed PPIs, and 16.0% ICS, prior to IPF diagnosis. Regular prescribing of PPIs and ICS was positively associated with hospitalisation for pneumonia; the adjusted HR for pneumonia hospitalisation comparing regular PPI users with non-users was 1.14 (95%CI: 1.04–1.24); for regular ICS users the corresponding HR was 1.40 (95%CI: 1.25–1.55). We also observed a small increased risk for all-cause mortality in the “regular ICS user” group compared with the “non-user” control group (HRadj=1.19, 1.06–1.33). We found no evidence of an association between PPI prescribing and all-cause mortality.ConclusionProlonged prescription of medications used to treat common comorbidities in IPF may be associated with increased risks for severe respiratory infections. These findings point to a need to adopt an adequate risk-benefit balance approach to the prescribing of ICS-containing inhalers and PPIs in people with IPF without evidence of comorbidities, especially older patients and/or those with more advanced disease in whom respiratory infections are more likely to result in poorer outcomes.

  • Open Access

    The operational experience of private owners of small-sized care homes in China: a qualitative study

    by Zhang Xiuxiang, Xia Qinghua, Jennifer K. Quint, Ann D. Morgan, Brendan McCormack, Xiubin Zhang

    Background: Private small-sized care homes (<50 beds) have proliferated across China, however, until recently little was known about the characteristics of such institutions, and the challenges and the problems faced by their owners. This study aimed to explore the characteristics of small-sized, privately-owned care homes in the People’s Republic of China; and to understand the motivation and challenges faced by their owners. Methods: This study used an interpretative phenomenological analysis approach of qualitative research. Owners of eight small-sized private care homes located in two cities of Henan Province, China, were interviewed using semi-structured interviews. Results: Four themes and eight subthemes were identified: 1. Motivation for establishing a care home business; 2. Certification and establishing a legal footing for the business; 3. Operational challenges; 4. Future business development. The study found that the development of privately owned small-sized care homes faced great challenges and critical survival problems due to policies, staffing, and management issues. There is a lack of regulations about the safety and quality of care provided for older people and a lack of legal protections for the owners of small-sized private care homes. Conclusion: The study suggests that formal regulations and provisions are needed to support these smaller-sized private care homes. Monitoring is also needed to ensure the quality of care. It also suggests that there needs more support by policymakers as well as provision monitoring services to improve quality of care in these care homes. Care regulations and standards are not unique to China so findings from this study can be applied to places where there are similar situations or if there are aged care services still developing.


  • Open Access

    Recent trends in asthma diagnosis, preschool wheeze diagnosis and asthma exacerbations in English children and adolescents: a SABINA Jr study

    by Constantinos Kallis, Ekaterina Maslova, Ann D Morgan, Ian Sinha, Graham Roberts, Ralf J P van der Valk, Jennifer K Quint, Trung N Tran

    Background: Asthma-related burden remains poorly characterised in children in the UK. We quantified recent trends in asthma prevalence and burden in a UK population-based cohort (1‒17-year-olds).Methods: The Clinical Practice Research Datalink Aurum database (2008‒2018) was used to assess annual asthma incidence and prevalence in 1‒17-year-olds and preschool wheeze in 1‒5-year-olds, stratified by sex and age. During the same period, annual asthma exacerbation rates were assessed in those with either a diagnosis of preschool wheeze or asthma.Results: Annual asthma incidence rates decreased by 51% from 1403.4 (95% CI 1383.7 to 1423.2) in 2008 to 688.0 (95% CI 676.3 to 699.9) per 105person-years (PYs) in 2018, with the most pronounced decrease observed in 1‒5-year olds (decreasing by 65%, from 2556.9 (95% CI 2509.8 to 2604.7) to 892.3 (95% CI 866.9 to 918.3) per 105PYs). The corresponding decreases for the 6‒11- and 12‒17-year-olds were 36% (1139.9 (95% CI 1110.6 to 1169.7) to 739.9 (95% CI 720.5 to 759.8)) and 20% (572.3 (95% CI 550.4 to 594.9) to 459.5 (95% CI 442.9 to 476.4)) per 105PYs, respectively. The incidence of preschool wheeze decreased over time and was slightly more pronounced in the 1‒3 year-olds than in the 4-year-olds. Prevalence of asthma and preschool wheeze also decreased over time, from 18.0% overall in 2008 to 10.2% in 2018 for asthma. Exacerbation rates increased over time from 1.33 (95% CI 1.31 to 1.35) per 10 PYs in 2008 to 1.81 (95% CI 1.78 to 1.83) per 10 PYs in 2018.Conclusion: Paediatric asthma incidence decreased in the UK since 2008, particularly in 1–5-year-olds; this was accompanied by a decline in asthma prevalence. Preschool wheeze incidence also decreased in this age group. However, exacerbation rates have been increasing.